MTOR and systemic lupus erythematosus: mTOR pathway modulators and glucose metabolism inhibitors have demonstrated therapeutic benefit in experimental models of SLE, and rapamycin has also been tested in animal models of SLE and human rheumatic diseases [66,67,68,69].